Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 4
1994 12
1995 8
1996 8
1997 9
1998 8
1999 12
2000 10
2001 7
2002 10
2003 11
2004 9
2005 3
2006 13
2007 3
2008 11
2009 4
2010 5
2012 6
2013 5
2014 4
2015 2
2016 5
2017 4
2018 3
2019 4
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

173 results
Results by year
Filters applied: . Clear all
Page 1
Randomized trial of intravenous iron-induced hypophosphatemia.
Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Wolf M, et al. JCI Insight. 2018 Dec 6;3(23):e124486. doi: 10.1172/jci.insight.124486. JCI Insight. 2018. PMID: 30518682 Free PMC article. Clinical Trial.
METHODS: In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose (n = 1,000) or ferumoxytol (n = 9 …
METHODS: In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we comp …
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, Chertow GM, Krop JS. Adkinson NF, et al. Am J Hematol. 2018 May;93(5):683-690. doi: 10.1002/ajh.25060. Epub 2018 Feb 24. Am J Hematol. 2018. PMID: 29417614 Free PMC article. Clinical Trial.
Composite incidences of moderate-to-severe HSRs, including anaphylaxis, or moderate-to-severe hypotension from baseline to week 5 (primary safety end point) were 0.6% and 0.7% in the ferumoxytol and FCM groups, respectively, with ferumoxytol noninferior to FCM. ...I …
Composite incidences of moderate-to-severe HSRs, including anaphylaxis, or moderate-to-severe hypotension from baseline to week 5 (primary s …
Pharmacokinetics of Ferumoxytol in the Abdomen and Pelvis: A Dosing Study with 1.5- and 3.0-T MRI Relaxometry.
Wells SA, Schubert T, Motosugi U, Sharma SD, Campo CA, Kinner S, Woo KM, Hernando D, Reeder SB. Wells SA, et al. Radiology. 2020 Jan;294(1):108-116. doi: 10.1148/radiol.2019190489. Epub 2019 Nov 12. Radiology. 2020. PMID: 31714191 Free article. Clinical Trial.
There was no difference in R2* change between non-MPS and LN R2* at any time (range, 1-71 sec(-1) vs 0-50 sec(-1); P = .06 to P = .97). Conclusion The pharmacokinetics of ferumoxytol in lymph nodes are distinct from those in mononuclear phagocyte system (MPS) organs …
There was no difference in R2* change between non-MPS and LN R2* at any time (range, 1-71 sec(-1) vs 0-50 sec(-1); P = .06 to P = .97 …
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Karussis D, et al. Arch Neurol. 2010 Oct;67(10):1187-94. doi: 10.1001/archneurol.2010.248. Arch Neurol. 2010. PMID: 20937945 Free PMC article. Clinical Trial.
In 9 cases, MSCs were magnetically labeled with the superparamagnetic iron oxide ferumoxides (Feridex). MAIN OUTCOME MEASURES: The main outcome measure was the recording of side effects. ...
In 9 cases, MSCs were magnetically labeled with the superparamagnetic iron oxide ferumoxides (Feridex). MAIN OUTCOME MEASURES: The ma …
Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.
Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, Madan RA, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL. Turkbey B, et al. AJR Am J Roentgenol. 2020 Jan;214(1):105-113. doi: 10.2214/AJR.19.21264. Epub 2019 Oct 15. AJR Am J Roentgenol. 2020. PMID: 31613660 Free PMC article. Clinical Trial.
The SI difference between benign and malignant LNs on ferumoxytol-enhanced MRL appears similar 24 and 48 hours after ferumoxytol injection, suggesting that imaging can be performed safely within 1 or 2 days of injection. Although ferumoxytol-enhanced MRL can …
The SI difference between benign and malignant LNs on ferumoxytol-enhanced MRL appears similar 24 and 48 hours after ferumoxytol
Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.
Muehe AM, Feng D, von Eyben R, Luna-Fineman S, Link MP, Muthig T, Huddleston AE, Neuwelt EA, Daldrup-Link HE. Muehe AM, et al. Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230. Invest Radiol. 2016. PMID: 26656202 Free PMC article. Clinical Trial.
OBJECTIVE: The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children. ...RESULTS: Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 …
OBJECTIVE: The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contras …
Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial.
Macdougall IC, Strauss WE, Dahl NV, Bernard K, Li Z. Macdougall IC, et al. Clin Nephrol. 2019 Apr;91(4):237-245. doi: 10.5414/CN109512. Clin Nephrol. 2019. PMID: 30802204 Free PMC article. Clinical Trial.
Patients with IDA and CKD undergoing hemodialysis were randomized 2:1 to ferumoxytol 1.02 g (2 510 mg) or iron sucrose 1.0 g (10 100 mg) for a 5-week treatment period (TP). ...Adverse events were recorded during the study. RESULTS: Overall, 293 patients received ferumox
Patients with IDA and CKD undergoing hemodialysis were randomized 2:1 to ferumoxytol 1.02 g (2 510 mg) or iron sucrose 1.0 g (10 100 …
Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.
Muehe AM, Siedek F, Theruvath AJ, Seekins J, Spunt SL, Pribnow A, Hazard FK, Liang T, Daldrup-Link H. Muehe AM, et al. Theranostics. 2020 Feb 18;10(8):3612-3621. doi: 10.7150/thno.40606. eCollection 2020. Theranostics. 2020. PMID: 32206111 Free PMC article. Clinical Trial.
Ferumoxytol is an FDA-approved iron supplement for the treatment of anemia and has been used "off-label" as an MRI contrast agent in this study. Forty-two children (7-18 years, 29 male, 13 female) received a (18)F-FDG PET/MRI at 2 (n=20) or 24 hours (h) (n=22) after intrav
Ferumoxytol is an FDA-approved iron supplement for the treatment of anemia and has been used "off-label" as an MRI contrast agent in
A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
Cohen J, Khudanyan A, Lu J, Wing J, Olson S, Deloughery T, Shatzel JJ. Cohen J, et al. Am J Hematol. 2020 Dec;95(12):1572-1577. doi: 10.1002/ajh.25995. Epub 2020 Oct 12. Am J Hematol. 2020. PMID: 32918335 Clinical Trial.
Previous studies of ferumoxytol alone support the effectiveness and safety of the single-dose regimen, but there is a paucity of data directly comparing single-dose ferumoxytol to other single-dose IV iron formulations. ...All 906 patients were included for the seco …
Previous studies of ferumoxytol alone support the effectiveness and safety of the single-dose regimen, but there is a paucity of data …
The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC, Dahl NV, Bernard K, Li Z, Batycky A, Strauss WE. Macdougall IC, et al. BMC Nephrol. 2017 Apr 3;18(1):117. doi: 10.1186/s12882-017-0523-8. BMC Nephrol. 2017. PMID: 28372549 Free PMC article. Clinical Trial.
While correcting anemia in these patients is an important therapeutic goal, there is a lack of long-term trials directly comparing intravenous iron therapies in patients with CKD receiving hemodialysis. METHODS/DESIGN: The Ferumoxytol for Anemia of CKD Trial (FACT) is a 13 …
While correcting anemia in these patients is an important therapeutic goal, there is a lack of long-term trials directly comparing intraveno …
173 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page